Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Frequently asked questions
What sector does Acrivon Therapeutics Inc. Common Stock (ACRV) operate in?
Acrivon Therapeutics Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Acrivon Therapeutics Inc. Common Stock (ACRV) current stock price?
As of the latest data, Acrivon Therapeutics Inc. Common Stock stock price is $1.95, with a previous close of $1.85. Acrivon Therapeutics Inc. Common Stock gained $0.10 in the last trading session, representing a 5.41% increase.
What is Acrivon Therapeutics Inc. Common Stock (ACRV) current market capitalization?
Acrivon Therapeutics Inc. Common Stock market cap is approximately 83.46 million.
What is Acrivon Therapeutics Inc. Common Stock (ACRV) Earnings Per Share (EPS)?
The trailing EPS is -$1.88, and the forward EPS is -$1.73.
What is Acrivon Therapeutics Inc. Common Stock (ACRV) EBITDA?
Acrivon Therapeutics Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -18.67 million.
Does Acrivon Therapeutics Inc. Common Stock (ACRV) pay dividends?
No. Acrivon Therapeutics Inc. Common Stock does not pay a dividend.
What is Acrivon Therapeutics Inc. Common Stock (ACRV) beta (volatility) score?
Acrivon Therapeutics Inc. Common Stock has a beta of 1.863, suggesting it is more volatile than the market.
